Bevacizumab for recurrent GBM
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-BEVACIZUMAB |
|---|
| ID | REG-BEVACIZUMAB-GBM |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-07 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-CNS-2025 |
Notes
Thin regimen stub added to resolve existing recurrent GBM bevacizumab references.
Used By
Indication
IND-GBM-RECURRENT-BEVACIZUMAB- IND-GBM-RECURRENT-BEVACIZUMAB